Where is Nuvation Bio Inc. (NUVB) Headed According to Wall Street Analysts?

Group 1 - Nuvation Bio Inc. (NYSE:NUVB) is recognized as a promising small-cap stock with significant growth potential, particularly following the amendment of the SIGMA study protocol to expand it to a Phase 3 trial for safusidenib, a targeted inhibitor of mutant IDH1 [1] - The updated protocol allows for broader patient eligibility, including those with grades 2 and 3 IDH1-mutant astrocytoma with high-risk features, as well as grade 4 IDH1-mutant astrocytoma after standard treatments [2] - Truist has raised its price target for Nuvation Bio to $13 from $11 while maintaining a Buy rating, citing strong initial uptake of the Ibtrozi franchise as a key factor [3] Group 2 - Nuvation Bio is focused on developing innovative therapeutic candidates to address unmet needs in oncology, with several clinical-stage candidates in its pipeline, including a BET inhibitor and a ROS1 inhibitor [4]